Literature DB >> 12820821

Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Mori J Krantz1, Ilana B Kutinsky, Alastair D Robertson, Philip S Mehler.   

Abstract

STUDY
OBJECTIVE: To investigate the relationship between the daily dose of the synthetic opioid methadone and the corrected QT (QTc) interval in a series of methadone-treated patients who developed torsade de pointes.
DESIGN: Retrospective case series analysis.
SETTING: Outpatient pain management center and methadone maintenance treatment programs. PATIENTS: Seventeen patients who developed torsade de pointes while receiving very high daily doses of methadone.
MEASUREMENTS AND MAIN RESULTS: The QTc intervals were calculated for each patient. The relationship between daily methadone dose and QTc interval was assessed and adjusted for clinical characteristics that may have independently prolonged cardiac repolarization. The mean QTc interval was 615 +/- 77 msec. Multiple linear regression indicated that only the daily methadone dose was predictive of the QTc interval (r = +0.51, p = 0.03). All other variables examined, such as age, sex, presence of hypokalemia or structural heart disease, and presence of QT-prolonging drugs, were not predictive of the QTc interval (minimum p = 0.28).
CONCLUSION: In this series, the daily methadone dose correlated positively with the QTc interval. This finding supports the possibility that methadone contributed to the development of arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820821     DOI: 10.1592/phco.23.6.802.32186

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  44 in total

1.  Can methadone prolong the QT interval?

Authors:  J A Decerf; B Gressens; C Brohet; A Liolios; P Hantson
Journal:  Intensive Care Med       Date:  2004-06-08       Impact factor: 17.440

Review 2.  [Maintenance treatment of opiate addicts].

Authors:  N Scherbaum
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 3.  Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale?

Authors:  Sobia Mujtaba; Jorge Romero; Cynthia C Taub
Journal:  J Cardiovasc Dis Res       Date:  2013-11-16

4.  The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na⁺ channel, Na(v)1.5.

Authors:  V Schulze; C Stoetzer; A O O'Reilly; E Eberhardt; N Foadi; J Ahrens; F Wegner; A Lampert; J de la Roche; A Leffler
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.

Authors:  Rashmi R Shah; Joel Morganroth; Robert B Kleiman
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

6.  Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain.

Authors:  Tara A Macey; Melissa B Weimer; Elizabeth M Grimaldi; Steven K Dobscha; Benjamin J Morasco
Journal:  J Opioid Manag       Date:  2013 Sep-Oct

7.  Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest.

Authors:  Geoffrey Walton; Seonaid Nolan; Christy Sutherland; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2015-09-21

8.  Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort.

Authors:  Gavin Bart; Zachary Wyman; Qi Wang; James S Hodges; Rehan Karim; Bradley A Bart
Journal:  J Addict Med       Date:  2017 Nov/Dec       Impact factor: 3.702

9.  Effects of Methadone on Corrected Q-T Interval Prolongation in Critically Ill Children.

Authors:  Travis S Heath; Rachel G Greenberg; Susan R Hupp; David A Turner; Christoph P Hornik; Kanecia O Zimmerman
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 10.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.